Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8943029

—

5e35f7f7-85ae-5919-98cb-238ee8ffe861

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.520
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
  • COAGULATION+0.310
  • MYOGENESIS+0.280
  • HEDGEHOG_SIGNALING+0.240
  • KRAS_SIGNALING_DN+0.240
  • PANCREAS_BETA_CELLS+0.240
  • APICAL_JUNCTION+0.220
  • WNT_BETA_CATENIN_SIGNALING+0.190
  • ALLOGRAFT_REJECTION+0.180

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.540
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.450
  • PROTEIN_SECRETION-0.390
  • UNFOLDED_PROTEIN_RESPONSE-0.350
  • ADIPOGENESIS-0.340
  • FATTY_ACID_METABOLISM-0.340
  • DNA_REPAIR-0.330
  • HEME_METABOLISM-0.330
  • MTORC1_SIGNALING-0.310
  • PEROXISOME-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1DRR168520
bladder-landscape@3
——0.822
23d8cce44-2cc8-464c-930c-78eb705bc4c8
colon-landscapes@1
——0.820
3BS_C41DJZ1F
brain-umap@2
high-grade glioma—0.804
466e5440a-6b08-43cc-b007-82ac3f5221d1
colon-landscapes@1
——0.801
5SRR615515
brain-umap@2
GTEX—0.800
6MNG131
mng-umap@100
——0.797
7TCGA-22-1002-01A-01R-0692-07
lung-landscapes@6
—cohortSQ10.793
8SRR6013528
lung-landscapes@6
—cohortSQ10.787
920030032.TNBC
breast-umap@18
—D0.784
10SRR8943036
bladder-landscape@3
——0.784

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.520Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.490Inavolisib— uncovered
COAGULATION0.310Binimetinib— uncovered
MYOGENESIS0.280Inavolisib— uncovered
HEDGEHOG_SIGNALING0.240Inavolisib— uncovered
KRAS_SIGNALING_DN0.240Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.240Cobimetinib— uncovered
APICAL_JUNCTION0.220Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered
ALLOGRAFT_REJECTION0.180Idelalisib— uncovered
APICAL_SURFACE0.180Temsirolimus— uncovered
INFLAMMATORY_RESPONSE0.180Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.160Inavolisib— uncovered
MYC_TARGETS_V20.120Idelalisib— uncovered
APOPTOSIS0.090Idelalisib— uncovered
COMPLEMENT0.090Inavolisib— uncovered
IL2_STAT5_SIGNALING0.080Idelalisib— uncovered
TGF_BETA_SIGNALING0.080Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.050Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.050Inavolisib— uncovered